CS265249B2 - Process for preparing thermal stable antibiotic preparates - Google Patents

Process for preparing thermal stable antibiotic preparates Download PDF

Info

Publication number
CS265249B2
CS265249B2 CS88158A CS15888A CS265249B2 CS 265249 B2 CS265249 B2 CS 265249B2 CS 88158 A CS88158 A CS 88158A CS 15888 A CS15888 A CS 15888A CS 265249 B2 CS265249 B2 CS 265249B2
Authority
CS
Czechoslovakia
Prior art keywords
zwitterion
salt
molar ratio
sodium chloride
chloride
Prior art date
Application number
CS88158A
Other languages
Czech (cs)
English (en)
Other versions
CS15888A2 (en
Inventor
Murray Arthur Kaplan
Joseph Ballard Dr Bogardus
Nageswara R Palepu
Original Assignee
Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Co filed Critical Bristol Myers Co
Publication of CS15888A2 publication Critical patent/CS15888A2/cs
Publication of CS265249B2 publication Critical patent/CS265249B2/cs

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cephalosporin Compounds (AREA)
CS88158A 1987-01-09 1988-01-06 Process for preparing thermal stable antibiotic preparates CS265249B2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/001,945 US4808617A (en) 1985-12-18 1987-01-09 Lyophilized or precipitated cephalosporin zwitterion and salt combination

Publications (2)

Publication Number Publication Date
CS15888A2 CS15888A2 (en) 1989-01-12
CS265249B2 true CS265249B2 (en) 1989-10-13

Family

ID=21698538

Family Applications (1)

Application Number Title Priority Date Filing Date
CS88158A CS265249B2 (en) 1987-01-09 1988-01-06 Process for preparing thermal stable antibiotic preparates

Country Status (33)

Country Link
US (1) US4808617A (pt)
JP (1) JP2568226B2 (pt)
KR (1) KR950010154B1 (pt)
AR (1) AR243501A1 (pt)
AT (1) AT388672B (pt)
AU (1) AU606361B2 (pt)
BE (1) BE1002114A3 (pt)
CA (1) CA1307464C (pt)
CH (1) CH676202A5 (pt)
CS (1) CS265249B2 (pt)
CY (1) CY1679A (pt)
DD (1) DD264614A5 (pt)
DE (1) DE3740588C2 (pt)
DK (1) DK166404B1 (pt)
ES (1) ES2008951A6 (pt)
FI (1) FI89006C (pt)
FR (1) FR2609396B1 (pt)
GB (1) GB2199746B (pt)
GR (1) GR871860B (pt)
HK (1) HK5593A (pt)
HU (1) HU199686B (pt)
IE (1) IE61238B1 (pt)
IL (1) IL84346A (pt)
IT (1) IT1215666B (pt)
LU (1) LU87102A1 (pt)
NL (1) NL193266C (pt)
OA (1) OA08796A (pt)
PT (1) PT86157B (pt)
SE (1) SE467910B (pt)
SG (1) SG114792G (pt)
SU (1) SU1575942A3 (pt)
YU (1) YU46689B (pt)
ZA (1) ZA88114B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4910301A (en) * 1985-08-05 1990-03-20 Bristol-Myers Company Cefepime cephalosporin salts
CA2011116C (en) * 1989-03-06 1999-11-16 Murray A. Kaplan Lyophilized bmy-28142 dihydrochloride for parenteral use
DE19539574A1 (de) 1995-10-25 1997-04-30 Boehringer Mannheim Gmbh Zubereitungen und Verfahren zur Stabilisierung biologischer Materialien mittels Trocknungsverfahren ohne Einfrieren
WO2005094800A2 (en) * 2004-03-31 2005-10-13 Lupin Ltd. A co-precipitated cefepime composition and process for preparation thereof
WO2006109324A2 (en) * 2005-04-13 2006-10-19 Lupin Limited Processes for preparation of amorphous cefepime acid addition salts
JP5491119B2 (ja) * 2009-10-02 2014-05-14 日東電工株式会社 薬物含有微粒子を含む医薬組成物およびその製造方法
US9320740B2 (en) 2013-03-15 2016-04-26 Merck Sharp & Dohme Corp. Ceftolozane-tazobactam pharmaceutical compositions
US9872906B2 (en) 2013-03-15 2018-01-23 Merck Sharp & Dohme Corp. Ceftolozane antibiotic compositions
KR102226197B1 (ko) 2013-03-15 2021-03-11 머크 샤프 앤드 돔 코포레이션 세프톨로잔 항균성 조성물
WO2015035376A2 (en) 2013-09-09 2015-03-12 Calixa Therapeutics, Inc. Treating infections with ceftolozane/tazobactam in subjects having impaired renal function
US20150094293A1 (en) 2013-09-27 2015-04-02 Calixa Therapeutics, Inc. Solid forms of ceftolozane
WO2016035846A1 (ja) 2014-09-04 2016-03-10 塩野義製薬株式会社 カテコール基を有するセファロスポリン類を含有する製剤

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3953439A (en) * 1973-08-01 1976-04-27 Smithkline Corporation Substituted phenylglycylcephalosporins
US4029655A (en) * 1975-04-11 1977-06-14 Eli Lilly And Company Method of preparing stable sterile crystalline cephalosporins for parenteral administration
CA1213882A (en) * 1982-03-04 1986-11-12 Jun Okumura Cephalosporins
US4406899A (en) * 1982-03-04 1983-09-27 Bristol-Myers Company Cephalosporins
JPS6045514A (ja) * 1983-08-22 1985-03-12 Shionogi & Co Ltd 安定な抗菌性凍結乾燥製剤
US4604386A (en) * 1984-07-09 1986-08-05 Eli Lilly And Company 3-(alkynylalkyloxy) cephalosporins
JPS61130223A (ja) * 1984-11-28 1986-06-18 Shionogi & Co Ltd 抗菌性凍結乾燥製剤
FR2585705B1 (fr) * 1985-08-05 1989-01-13 Bristol Myers Co Sels de cephalosporine et compositions injectables

Also Published As

Publication number Publication date
IE61238B1 (en) 1994-10-19
NL193266C (nl) 1999-05-06
LU87102A1 (fr) 1988-08-23
IL84346A0 (en) 1988-04-29
NL193266B (nl) 1999-01-04
AT388672B (de) 1989-08-10
AU8085687A (en) 1989-05-11
CS15888A2 (en) 1989-01-12
DK577387A (da) 1988-07-10
KR950010154B1 (ko) 1995-09-11
JP2568226B2 (ja) 1996-12-25
ZA88114B (pt) 1988-06-27
KR880008811A (ko) 1988-09-13
IE872970L (en) 1988-07-09
PT86157B (pt) 1991-02-08
DK577387D0 (da) 1987-11-03
PT86157A (en) 1987-12-01
IT8819013A0 (it) 1988-01-07
CA1307464C (en) 1992-09-15
DE3740588A1 (de) 1988-07-21
AR243501A1 (es) 1993-08-31
IT1215666B (it) 1990-02-22
GR871860B (en) 1988-05-10
HK5593A (en) 1993-02-05
JPS63208522A (ja) 1988-08-30
SE467910B (sv) 1992-10-05
ES2008951A6 (es) 1989-08-16
NL8800025A (nl) 1988-08-01
DK166404B1 (da) 1993-05-17
ATA341687A (de) 1989-01-15
YU46689B (sh) 1994-04-05
SG114792G (en) 1992-12-24
DE3740588C2 (de) 1996-07-11
IL84346A (en) 1992-05-25
FI89006C (fi) 1993-08-10
AU606361B2 (en) 1991-02-07
SE8800036L (sv) 1988-07-10
FI875122A0 (fi) 1987-11-19
GB2199746A (en) 1988-07-20
GB8725875D0 (en) 1987-12-09
FR2609396B1 (fr) 1993-01-29
OA08796A (fr) 1989-03-31
HU199686B (en) 1990-03-28
YU2388A (en) 1989-10-31
FR2609396A1 (fr) 1988-07-15
SU1575942A3 (ru) 1990-06-30
SE8800036D0 (sv) 1988-01-08
US4808617A (en) 1989-02-28
GB2199746B (en) 1990-10-24
FI875122A (fi) 1988-07-10
DD264614A5 (de) 1989-02-08
FI89006B (fi) 1993-04-30
HUT46223A (en) 1988-10-28
CH676202A5 (pt) 1990-12-28
BE1002114A3 (fr) 1990-07-10
CY1679A (en) 1993-10-10

Similar Documents

Publication Publication Date Title
EP2062582B1 (en) Antibiotic composition comprising beta-lactam antibiotics, aminoglycosides and buffers
EP2062581B1 (en) The antibiotics composition comprising beta-lactam antibiotics and ionic chelating agents
KR0180798B1 (ko) 결정성 페니실린 유도체, 그의 제법 및 용도
KR100621291B1 (ko) 세팔로스포린 화합물을 포함하는 제형 및 고양이 및개에서 박테리아 감염을 치료하는 그의 용도
AU2004229407B2 (en) Compositions containing piperacillin and tazobactam useful for injection
CN110279698B (zh) 头孢特咯瓒抗生素组合物
CS265249B2 (en) Process for preparing thermal stable antibiotic preparates
US20140274996A1 (en) Tazobactam and ceftolozane antibiotic compositions
CZ281602B6 (cs) Krystalické adičních soli 7-/alfa-(2-aminothiazol-4-yl)-alfa-(Z)-methoxyiminoacetamido/-3-/(1-methyl-1-pyrrolidinio)-methyl/-3-cefem-4-karboxylátu, způsob výroby a farmaceutické prostředky s jejich obsahem
DK166541B1 (da) Fremgangsmaade til isolering af isosilybinfrit silibinin
JPH0840907A (ja) セファロスポリン注射剤
CS276849B6 (en) Process for preparing heat stable crystalline mono chloride
IE57587B1 (en) Stable antibacterial lyophilizates
DK158443B (da) Fremgangsmaade til stabilisering af et lyophiliseret praeparat indeholdende et alkalimetalsalt af en 7beta-(alfa-carboxy-alfa-arylacetamido)-7alfa-methoxy-3-heterocyklisk thiomethyl-1-dethia-1-oxa-3-cephem-4-carboxylsyre
JPH02273684A (ja) 非経口用凍結乾燥bmy―28142ジ塩酸塩
EP0169700B1 (en) Improved pharmaceutical formulations for ceftazidime
CA1307206C (en) Antibacterial agent for mammal use comprising cephalosporin derivatives as an effective ingredient
JPH0782149A (ja) セフェム系抗生物質の安定化製剤
JP2004269401A (ja) 凍結乾燥製剤
NL8403948A (nl) Antibacteriele geneesmiddelsamenstelling.
Acred Therapeutische und kinetische Eigenschaften von Ceftazidim bei Tieren

Legal Events

Date Code Title Description
IF00 In force as of 2000-06-30 in czech republic
MM4A Patent lapsed due to non-payment of fee

Effective date: 20060106